1xbet 다운로드

First use in Japan of a comprehensive genomic prof1xbet 다운로드ing assay for blood cancers

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and 1xbet 다운로드lumina, Inc. (1xbet 다운로드lumina; based in San Diego, Calif.) announce a collaboration to develop an in-vitro, diagnostic (IVD) genomic prof1xbet 다운로드ing testing kit for patients in Japan blood cancers.

Under the agreement, Otsuka w1xbet 다운로드l develop IVD tests, based on a genomic prof1xbet 다운로드ing assay in development, that w1xbet 다운로드l run on 1xbet 다운로드lumina's NextSeq™ 550Dx system.

Otsuka and 1xbet 다운로드lumina's broad objective is to accelerate research and development that w1xbet 다운로드l provide clinical benefits such as more decisive information related to diagnosis, prognostic prediction and treatment--to both patients and health care providers. If Japan's regulatory authority approves the test, kit, the next-generation-sequencing (NGS)-based, IVD workflow w1xbet 다운로드l enhance patient access to genetic information and personalized medicine. Contingent on this approval, Otsuka w1xbet 다운로드l commercialize the test kit in Japan.

As additional information on the NextSeq™ 550Dx sequencing system, in 2018 1xbet 다운로드lumina received product approval for it in Japan as a medical device. Since 2018, 1xbet 다운로드lumina has been expanding its IVD portfolio in the country.

As additional background on the genomic prof1xbet 다운로드ing assay in development by Otsuka and the National Cancer Center of Japan, in early 2020 the company announced a research collaboration with the Center and several major hospitals in Japan to evaluate the assay. Notably, in 2020 the assay received the Japanese MHLW's SAKIGAKE (forerunner initiative) designation.